There is currently little evidence that the information provided by personal genomics companies—such as 23andMe and Navigenics—on a direct-to-consumer (DTC) basis, has any real health value. To be fair, research directly on-point is lacking. However, emerging analysis suggests that the personal genomic information that can be obtained from these companies is simply not of a nature that can support useful health applications (Kraft and Hunter 2009; Jakobsdottir et al. 2009; Magnus et al. 2009).